uniQure N.V. (NASDAQ:QURE) has been given a consensus recommendation of “Hold” by the nine research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $12.45.

Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of uniQure N.V. from a “buy” rating to a “sell” rating in a report on Wednesday, May 17th. ValuEngine upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Oppenheimer Holdings, Inc. set a $17.00 target price on shares of uniQure N.V. and gave the company a “buy” rating in a report on Tuesday, May 16th. Cowen and Company reiterated a “buy” rating on shares of uniQure N.V. in a report on Wednesday, May 24th. Finally, Chardan Capital set a $13.00 target price on shares of uniQure N.V. and gave the company a “buy” rating in a report on Sunday, July 23rd.

COPYRIGHT VIOLATION NOTICE: This story was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/19/uniqure-n-v-qure-receives-average-recommendation-of-hold-from-brokerages.html.

In other uniQure N.V. news, insider Harald Petry sold 49,300 shares of the business’s stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $6.02, for a total value of $296,786.00. Following the completion of the transaction, the insider now owns 27,753 shares in the company, valued at $167,073.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 173,460 shares of company stock valued at $1,042,986. Insiders own 0.64% of the company’s stock.

Several institutional investors have recently bought and sold shares of QURE. Mangrove Partners acquired a new position in uniQure N.V. during the second quarter valued at approximately $247,000. FMR LLC increased its position in uniQure N.V. by 4.1% in the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after buying an additional 61,650 shares during the period. JPMorgan Chase & Co. increased its position in uniQure N.V. by 33.5% in the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 14,659 shares during the period. Paloma Partners Management Co increased its position in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 74,605 shares during the period. Finally, Weiss Multi Strategy Advisers LLC increased its position in uniQure N.V. by 266.7% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 40,000 shares during the period. Institutional investors and hedge funds own 29.00% of the company’s stock.

Shares of uniQure N.V. (NASDAQ:QURE) traded down 3.78% on Friday, reaching $8.41. The company had a trading volume of 35,910 shares. The company’s 50 day moving average price is $7.71 and its 200-day moving average price is $6.20. The stock’s market capitalization is $214.96 million. uniQure N.V. has a 1-year low of $4.72 and a 1-year high of $9.15.

uniQure N.V. (NASDAQ:QURE) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative net margin of 203.99% and a negative return on equity of 135.97%. The company had revenue of $4.94 million during the quarter, compared to analyst estimates of $2.92 million. Equities analysts predict that uniQure N.V. will post ($3.04) EPS for the current year.

uniQure N.V. Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Analyst Recommendations for uniQure N.V. (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.